Oncolytics Biotech Inc
Research Oncolytics Biotech Inc (ONCY) on Bullrun: market cap USD 58.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerONCY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 58.58M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 9.44M
- Free cash flow-USD 8.14M
Valuation Snapshot
latest market cap is USD 58.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 28.76M | -USD 20.12M | n/a | -0.3 | USD 5.20M | USD 563.00K | -USD 3.80M |
| FY2024 | USD 0 | -USD 22.79M | -USD 20.06M | n/a | -0.3 | USD 11.08M | USD 761.00K | USD 3.30M |
| FY2023 | USD 0 | -USD 20.92M | -USD 21.45M | n/a | -0.31 | USD 26.32M | USD 318.86K | USD 20.78M |
| FY2022 | USD 0 | -USD 18.30M | -USD 17.25M | n/a | -0.32 | USD 8.60M | USD 274.83K | USD 19.53M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 58.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 93.98M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 72.82M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 99.09M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 96.22M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 76.51M | n/a | n/a | n/a |
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oncolytics Biotech Inc's market cap?
Oncolytics Biotech Inc's market capitalization is USD 58.58M.
What does Oncolytics Biotech Inc do?
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc.